Drug Approval | June 01, 2022
FDA approves Roche’s Evrysdi for use in babies under two months with SMA
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Auld is a seasoned Financial Executive with over 30 years of relevant experience
The product will be launched by NATCO's commercial partner Viatris.
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights how blockchain ensures the authenticity of products thereby, improves trust, traceability, and transparency across key sectors
Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
The integration and transition of the brands are expected to be completed by June 2022.
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Subscribe To Our Newsletter & Stay Updated
